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Brucella is a Gram-negative, facultative intracellular bacterium that causes zoonotic brucel-
losis in humans and various animals. Out of 10 classiﬁed Brucella species, B. melitensis,
B. abortus, B. suis, and B. canis are pathogenic to humans. In the past decade, the mech-
anisms of Brucella pathogenesis and host immunity have been extensively investigated
using the cutting edge systems biology and bioinformatics approaches.This article provides
a comprehensive review of the applications of Omics (including genomics, transcriptomics,
and proteomics) and bioinformatics technologies for the analysis of Brucella pathogenesis,
host immune responses, and vaccine targets. Based on more than 30 sequenced Brucella
genomes, comparative genomics is able to identify gene variations among Brucella strains
that help to explain host speciﬁcity and virulence differences among Brucella species.
Diverse transcriptomics and proteomics gene expression studies have been conducted to
analyze gene expression proﬁles of wild type Brucella strains and mutants under different
laboratory conditions. High throughput Omics analyses of host responses to infections
with virulent or attenuated Brucella strains have been focused on responses by mouse
and cattle macrophages, bovine trophoblastic cells, mouse and boar splenocytes, and ram
buffy coat. Differential serum responses in humans and rams to Brucella infections have
been analyzed using high throughput serum antibody screening technology. The Vaxign
reverse vaccinology has been used to predict many Brucella vaccine targets. More than
180 Brucella virulence factors and their gene interaction networks have been identiﬁed
using advanced literature mining methods. The recent development of community-based
Vaccine Ontology and Brucellosis Ontology provides an efﬁcient way for Brucella data
integration, exchange, and computer-assisted automated reasoning.
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INTRODUCTION
Brucella abortus is a Gram-negative, facultative intracellular bac-
terium that causes brucellosis in humans and many animals (Cor-
bel, 1997). The brucellae are taxonomically placed in the alpha-2
subdivision of the class Proteobacteria. There are 10 species of Bru-
cella based on preferential host speciﬁcity: B. melitensis (goats), B.
abortus (cattle), B. suis (swine), B. canis (dogs), B. ovis (sheep), B.
neotomae (desert mice),B. cetacea (cetacean),B. pinnipedia (seal),
B. microti (voles), and B. inopinata (unknown) (O’Callaghan and
Whatmore, 2011). Of 10 recognized species of Brucella, B. abor-
tus, B. melitensis, B. suis, and B. canis are pathogenic to humans.
Human infections with B. canis are rare. B. abortus, B. melitensis,
and B. suis are the most pathogenic to humans, have been iden-
tiﬁed as agents amenable for use in bio-terrorism, and are listed
as category B priority pathogens by the US Center for Disease
Control (CDC). Brucellosis is one of the most common zoonotic
diseases. It infects annually approximately 500,000 humans world-
wide. Upon entry into human or animals, the bacteria invade the
blood stream and lymphatics where they multiply inside phago-
cytic cells and eventually cause septicemia. Symptoms include
undulant fever, abortion, asthenia, endocarditis, and encephalitis.
Brucella lacks well-known bacterial virulence factors such as
cytolysins, capsules, exotoxins, secreted proteases, ﬁmbriae, phage-
encoded toxins, and virulence plasmids (DelVecchio et al., 2002;
Paulsen et al., 2002). The brucellae infect phagocytic macrophages
and non-phagocytic epithelial cells (e.g., HeLa cells) in vivo and
in vitro (Ko and Splitter, 2003; Kohler et al., 2003; Roop et al.,
2004). Brucella virulence relies on the ability to survive and repli-
cate in the vacuolar phagocytic compartments of macrophages.
Many Brucella virulent factors, such as lipopolysaccharide (LPS;
Lapaque et al., 2005), type IV secretion system (T4SS; O’Callaghan
et al., 1999; de Jong et al., 2008), and the BvrR/BvrS two-
component system (Guzman-Verri et al., 2002), have been iden-
tiﬁed to be critical in the intracellular process of Brucella inside
macrophages (Xiang et al., 2006). While these virulence factors
may not directly mediate clinical manifestations of brucellosis,
they are critical for Brucella to survive and replicate inside host
cells.While prolonged persistence of the brucellae in macrophages
leads to the chronic infection, extensive replication of the bacteria
in placental trophoblasts results in acute reproductive tract pathol-
ogy and abortion in natural hosts (Roop et al., 2009). Speciﬁcally,
the Brucella lifecycle contains two phases: (i) chronic infection
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of phagocytic macrophage leading to Brucella survival and repli-
cation, and (ii) acute infection of non-phagocytic epithelial cells
leading to reproductive tract pathology and abortion. Spleen and
liver are the organs that contain many bacterial cells after Brucella
invasion. After a majority of Brucella cells are killed in vivo, the
remaining Brucella cells will persist and live for a long time in vivo
(Hort et al., 2003).
Although antibodies speciﬁc for the O-antigen (i.e., O poly-
saccharide or O-side chain) of the lipopolysaccharide can confer
partial protection in some host species, cell-mediated immunity
(CMI) plays a critical role in protection against virulent Brucella
infection. The maturation and proinﬂammatory production of
cytokines of dendritic cells is critical for controlling Brucella infec-
tions (Macedo et al., 2008). Recently we found that B. abortus
vaccine strain RB51 and B. suis vaccine candidate VTRS1 induce
caspase-2-mediated apoptotic and necrotic macrophage cell death
(Chen and He, 2009; Chen et al., 2011). The programmed cell
death is inhibited by virulentBrucella strains. Caspase-2-mediated
cell death induced by vaccine strain RB51 may promote an effec-
tive Brucella antigen presentation by a cross-priming mechanism
(Bevan, 2006; Chen and He, 2009). Passive transfer assays with
mice suggest that both CD4+ and CD8+ T cells are important in
protective immunity against brucellosis (Araya et al., 1989; Araya
and Winter, 1990). To confer protection against B. abortus infec-
tion, immune CD4+ T cells secrete many cytokines, including
gamma interferon (IFN-γ) that stimulates the antimicrobial activ-
ity of macrophages (Jiang and Baldwin, 1993; Zhan and Cheers,
1993; He et al., 2001). A crucial role of IFN-γ in the resistance to
Brucella infection was demonstrated in mice by in vivo antibody
neutralization experiments (Zhan and Cheers, 1993) and an IFN-
γ knockout mouse study (Murphy et al., 2001). CD8+ cytotoxic T
lymphocytes (CTL) are critical in killing Brucella-infected target
cells (Oliveira and Splitter, 1995; He et al., 2001).
Brucella abortus strain RB51 and strain 19 and B. melitensis
strain Rev. 1 have been used as commercial animal brucellosis
vaccines (Schurig et al., 2002). Strain 19 is the ﬁrst effective live
attenuated Brucella vaccine widely used in the world. This smooth
strain induces anti-O-antigen antibody in the host. Since this sero-
logical response is used for brucellosis diagnosis in the ﬁeld, Strain
19-induced antibody response is often misdiagnosed as the sign of
virulent Brucella infection. Cattle brucellosis vaccine strain RB51
is a rough live attenuated B. abortus strain derived from smooth
virulent strain 2308 (Schurig et al., 1991). RB51 does not induce
an anti-O-antigen serological antibody response, thus does not
interfere with serological diagnosis. Rev. 1 protects sheep and
goats from infection with B. melitensis. However, these vaccine
strains cannot be used in humans due to their pathogenicity.
There is no safe, effective human brucellosis vaccine. However,
such a human vaccine is desired for improving public health and
biosafety. To rationally design a safe and effective brucellosis vac-
cine, it is important to further understand the mechanisms of
Brucella pathogenesis and protective Brucella immunity.
Systems biology aims to understand biological systems on a
system level using interdisciplinary technologies. In contrast to
the traditional reductionist molecular approach, which focuses
on understanding the roles of single genes or proteins, systems
biology applies a more holistic approach by studying networks
and the interactions between individual components of networks
(Kuster et al., 2011). The goal of systems biology is to under-
stand the structure, dynamics, and interactions of whole cells
rather than portions thereof. Systems biology treats an organ-
ism (e.g., Brucella and human) as an integrated cellular system
consisting of an interacting network of genes, proteins, and mole-
cular cellular components including their biochemical/biophysical
reactions. Biological data and software tools for data analysis are
two basic ingredients in systems biology. The high throughput
experimental “omics” (Omics) technologies, including genomics,
transcriptomics, proteomics, andmetabolomics, aremajor driving
forces of systems biology (Kay andWren, 2009; Zhang et al., 2010).
The development of genome-scale computational and bioinfor-
matic tools allows analysis and modeling of metabolic, regulatory
and signaling networks of the cell at the systems-level.
Bioinformatics is the application of a combination of computer
science, statistics,mathematics, and information technology to the
ﬁeld of biology and medicine. Bioinformatics enables the discov-
ery of new biological insights and creates a global perspective of
unifying principles in biology. Bioinformatics emerged as a scien-
tiﬁc ﬁeld in 1990s when large amounts of nucleotide and amino
acid sequences were generated. At the time, bioinformatics took
a role of generating and maintaining databases to store biological
information and to support sequence data analyses. Subsequently,
bioinformatics has evolved leading to the development of new
computational algorithms, statistics methods, and tools to inte-
grate, manage, and analyze various biological data including high
throughput Omics data and literature data.
Brucella research has beneﬁted from the application of cutting
edge systems biology and bioinformatics technologies. The avail-
ability of Brucella and host (e.g., human and mouse) genomes
allow comparative genomic analyses of host speciﬁcity, virulence
analysis, and rational vaccine target design.High throughput array
technologies have been developed for analyses of transcriptomics
and proteomics gene expression proﬁles of host and Brucella
in vitro and in vivo. These analyses have resulted in a better under-
standing of host–Brucella interactions and Brucella pathogenesis.
Advanced literature mining approaches are also used to identify
Brucella virulence factors and genetic interaction pathways. Vari-
ousBrucella databases are publicly accessible for query and analysis
of structured data. Recently, ongoing ontology studies have facil-
itated Brucella data integration and computer-assisted automated
reasoning. This article provides a comprehensive review of the
applications of advanced systems biology and bioinformatics to
the study of Brucella pathogenesis, host–Brucella interactions, and
for the development of Brucella vaccines.
COMPARATIVE BRUCELLA GENOMICS FOR
UNDERSTANDING BRUCELLA GENETIC CONSERVATION,
VARIABILITY, AND HOST SPECIFICITY
While the mechanism of Brucella host speciﬁcity is still unclear,
comparative Brucella genomics has permitted identiﬁcation of
gene variability among different Brucella species and strains,
resulting in a better understanding of Brucella virulence and
adaptation in different hosts.
The genome of B. melitensis strain 16M was ﬁrst sequenced
and published in 2002 (DelVecchio et al., 2002). Since then,B. suis
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strain 1330 (Paulsen et al., 2002), and B. abortus strains 2308
(Chain et al., 2005) and 9-941 (Halling et al., 2005), and vac-
cine B. abortus strain 19 (Crasta et al., 2008) have been sequenced
and published in peer-reviewed journals. As of October 11, 2011,
the NCBI genome sequence site has been found to contain 14
sequencedBrucella genomes1. Furthermore,25 additionalBrucella
genomes have been sequenced by the Broad Institute. These are
available for public query, download, and further analysis at URL:
http://www.broadinstitute.org/annotation/genome/brucella_gro
up/GenomeStats.html. Therefore, at least 39 Brucella strains have
been sequenced. With the increasing number of sequenced bacte-
rial genomes, it becomes possible to conduct a systematic compar-
ative analysis of whole genomes of different Brucella strains and
to dissect their genetic conservation and variability.
EachBrucella genome contains two circular chromosomes. The
size of Chromosome I and II approximates 2.2 and 1.1Mb, respec-
tively. There are about 3200–3400 genes in each genome. Based on
DNA–DNA hybridization studies, the genus Brucella is a highly
homogeneous group (>90% DNA identity among all nomen-
species; Verger et al., 2000). Ratushna et al. (2006) compared the
genome sequences of B. abortus strain 9-941, B. melitensis strain
16M, and B. suis strain 1330. A majority (>90%) of annotated
genes in these three genomes share 98–100% sequence identity at
a nucleotide level. A majority of differentiating genes among these
three species are located in large (∼20 kb) regions (Ratushna et al.,
2006). Whatmore et al. (2007) examined nine discrete genomic
loci that correspond to 4396 bp of sequence from 160 Brucella iso-
lates. A phylogeny analysis using the multilocus sequences showed
that four classical Brucella species, B. abortus, B. melitensis, B. ovis,
and B. neotomae are well-separated clusters in the phylogenic tree
structure. With the exception of biovar 5, B. suis isolates clus-
ter together. B. canis isolates are located on a phylogenic branch
closely related to B. suis biovar 3 and 4 isolates. Marine mammal
isolates represent a distinct cluster (Whatmore et al., 2007). The
major conclusion of the phylogenic tree analysis was veriﬁed by
another maximum likelihood phylogenetic analysis of the 10 Bru-
cella strains (Wattam et al., 2009). That B. suis is a single species
has been questioned since it has a broader host speciﬁcity but does
not have any identiﬁed species-speciﬁc markers (Moreno et al.,
2002).
Since limited genome diversity exists among different Brucella
species, a comparison of Brucella species whole genomes is a pow-
erful tool to identify Brucella gene variability that is responsible
for differences in host preference and virulence restriction. The
sequence insertion/deletion events may contribute to host speci-
ﬁcity between different Brucella species. Rajashekara et al. (2004)
used the complete genome sequence of B. melitensis 16M, a strain
highly pathogenic to humans, to construct a genomic microarray.
Hybridization of labeled genomic DNA from different Brucella
strains to this microarray identiﬁed 217 open reading frames
(ORFs) that were altered in ﬁve Brucella species, including B.
abortus, B. suis, B. canis, B. ovis, and B. neotomae. Many of the
ORFs are located in the 16M genome in nine regions (genomics
islands) ranging in size from 5 to 44 kb. Genomic islands lost
1http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi
in a given species are often restricted to that particular species
(Rajashekara et al., 2004). The genomic islands missing in B. ovis
are present in Brucella species pathogenic to humans. However, B.
neotomae, a non-pathogenic species in humans and domestic ani-
mals, also possesses these islands. Interestingly, the genetic islands
identiﬁed do not encode adhesins or secreted virulence factors
that contribute to host speciﬁcity in other bacterial species (Moon
et al., 1977; Tsolis et al., 1999; Inatsuka et al., 2005). It is likely
that adhesins and secreted virulence factors are encoded in con-
served loci where they are differentially expressed or inactivated
by point mutations. As seen in Bordetella species (Parkhill et al.,
2003), gene inactivation or altered gene regulation may contribute
to differences in host range and virulence of Brucella species in
humans.
Table 1 lists studies published on Brucella pathogenesis and
host immunity using high throughput transcriptomics and pro-
teomics methods. These diverse studies are described in detail in
the following sections.
ANALYSIS OF BRUCELLA GENE EXPRESSION PROFILES AND
REGULATORY RESPONSES FROM IN VITRO CULTURES
USING DNA MICROARRAYS
DNA microarrays have been used to delineate Brucella patho-
genesis mechanisms. Viadas et al. (2009) generated a Brucella
whole-genome DNA microarray based on a comprehensive col-
lection of B. melitensis ORF clones or ORFeomes. The Brucella
DNA microarray was used to determine the global transcriptional
proﬁle of B. abortus grown under laboratory conditions. Riboso-
mal proteins, Krebs cycle, and oxidative phosphorylation enzymes
were found to have overexpressed transcripts. T4SS virB operon,
ﬂagellar components, and other genes related to virulence and
intracellular growth were poorly transcribed. This report demon-
strated the usefulness of the ORFeome for the construction of a
PCR product microarray for analysis of global gene expression in
Brucella and may be applied to other microorganisms as well.
Rossetti et al. (2009) found that B. melitensis cells grown in
the late-log growth phase are more invasive in HeLa (a represen-
tative epithelial cell line) cells compared to the brucellae grown
to the mid-log or stationary growth phase. To identify candi-
date pathogen genes involved in invasion of epithelial cells, cDNA
microarrays were used to characterize genome-wide transcript
changes of B. melitensis genes in late-log growth phase (the most
invasive culture) compared to the stationary growth phase (the
least invasive culture). At the late logarithmic growth phase, viru-
lent B. melitensis is more invasive in HeLa epithelial cells than the
mid-logarithmic or stationary growth phases. Compared to the
stationary growth phase, 414 up- and 40 down-regulated genes
were identiﬁed in late logarithmic growth phase. The majority of
up-regulated genes in the late-log phase cultures were associated
with growth, including DNA replication, transcription, transla-
tion, intermediatemetabolism,energy production and conversion,
membrane transport, and biogenesis of the cell envelope and outer
membrane.Down-regulated geneswere distributed among several
functional categories (Rossetti et al., 2009).
The two-component BvrR/BvrS system is essential for B. abor-
tus virulence. To determine the genes regulated by BvrR/BvrS,
Viadas et al. (2010) performed a whole-genome microarray
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Table 1 | Reviewed omics studies in Brucella pathogenesis and host immunity.
Brucella spp. Host cells and spp. Temporal Reference
COMPARATIVE BRUCELLA GENOMICSANALYSIS BASED ON SEQUENCE BIOINFORMATICSANALYSIS
B. abortus, B. melitensis, B. suis – No Ratushna et al. (2006)
6 classical Brucella species – No Whatmore et al. (2007)
BRUCELLA GENOMEANALYSIS USINGWET-LAB BRUCELLA GENOMIC MICROARRAY
B. melitensis – No Rajashekara et al. (2004)
BRUCELLATRANSCRIPTOMIC PROFILES USING DNA MICROARRAY
B. melitensis – No Viadas et al. (2009)
B. melitensis – Yes Rossetti et al. (2009)
WT and bvrR B. abortus mutant – No Viadas et al. (2010)
WT and vjbR B. melitensis mutant – No Weeks et al. (2010)
WT and blxR B. melitensis mutant – No Rambow-Larsen et al. (2008)
BRUCELLA PROTEOMIC PROFILES USING PROTEOMICS MICROARRAY
B. abortus S2308 and S19 In mouse macrophages Yes Lamontagne et al. (2009)
B. suis In mouse macrophages No Al Dahouk et al. (2008)
B. melitensis In HeLa cells Yes Rossetti et al. (2011)
B. melitensis In human sera No Liang et al. (2011)
B. melitensis In goat and human sera No Liang et al. (2010)
BRUCELLA-INFECTED HOST TRANSCRIPTOMIC PROFILES USING DNA MICROARRAY
B. abortus Mouse macrophages No Eskra et al. (2003)
B. melitensis Mouse macrophages Yes He et al. (2006)
B. melitensis, B. neotomae, B. ovis Mouse macrophages No Covert et al. (2009)
B. suis Mouse macrophages Yes Chen et al. (2011)
B. abortus Cattle macrophages No Rossetti et al. (2010)
B. abortus Bovine trophoblastic cells No Carvalho Neta et al. (2008)
B. abortus, B. melitensis, virB mutants Mouse spleens No Roux et al. (2007)
B. suis biovar 2 Eurasian wild boar spleens No Galindo et al. (2010)
Rough B. ovis strain PA Ram buffy coat Yes Galindo et al. (2009a)
B. melitensis strain Rev 1 Ram buffy coat Yes Galindo et al. (2009b)
analysis using B. abortus RNAs obtained from wild type and bvrR
mutant cells grown in vitro under the same conditions. Among
127 differentially expressed genes, 83 were up-regulated and 44
were down-regulated in the bvrR mutant. Many genes involved in
cell envelope or outer membrane biogenesis, including the outer
membrane proteins (OMPs; Omp25a and Omp25d), lipoproteins,
stress response proteins, chaperones, ﬂagellar genes, ABC trans-
port protein, and genes for lipopolysaccharide (LPS) and fatty
acid biosynthesis, were differentially expressed. Ten genes related
to carbon metabolism (e.g., pckA and fumB) were up-regulated
in the bvrR mutant. Three denitriﬁcation genes (nirK, norC, and
nosZ ) were also regulated. The two-component system also affects
seven transcriptional regulators includingVjbR,ExoR,andOmpR.
Therefore, the Brucella BvrR/BvrS system modulates cell envelope
biogenesis, controls the carbon and nitrogen metabolism, and
interact with other regulators to ensure the survival of Brucella
in an extracellular environment as well as an intracellular niche
(Viadas et al., 2010).
The quorum sensing (QS) communication system regulates
gene expression in response to population density and often regu-
lates virulence determinants as well. QS typically follows produc-
tion of an auto inducer such as acyl-homoserine lactone (AHL).
Among the proteobacteria, the AHL signal is synthesized by luxI
and interacts with the transcriptional regulator LuxR. Deletion of
Brucella vjbR, a LuxR-like transcriptional regulator, greatly attenu-
ates intracellular survival of B. melitensis. To better deﬁne the role
of VjbR and QS in Brucella virulence and survival, Weeks et al.
(2010) usedmicroarrays to analyze gene expressionproﬁles of Bru-
cella under the control of VjbR and an AHL signal (N -dodecanoyl
homoserine lactone, C12-HSL). Speciﬁcally, wild type B. meliten-
sis and isogenicΔvjbR transcriptomes were grown in the presence
and absence of exogenous C12-HSL. A comparison of VjbR and
C12-HSL transcriptomes identiﬁed shared regulation of 127 genes.
Of these genes, all but three genes were inversely regulated. These
results suggest that C12-HSL functions via VjbR to reverse gene
expression. In the absence of VjbR and in the presence of C12-HSL,
48 genes were up-regulated at the stationary growth phase. The
differentially regulated genes included adhesins, proteases, antibi-
otic and toxin resistance genes, stress survival aids, transporters,
membrane biogenesis genes, amino acid metabolism and trans-
port, transcriptional regulators, energy production genes, and ﬂiF
and virB operons. Many of the differentially regulated genes have
been identiﬁed as virulence factors in other bacterial pathogens.
Therefore, it can be concluded that VjbR and C12-HSL contribute
to virulence and survival by regulating expression of virulence
mechanisms (Weeks et al., 2010).
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In addition to VjbR, the ﬁrst LuxR-type regulatory protein
identiﬁed in Brucella, Rambow-Larsen et al. (2008) identiﬁed a
second LuxR-type regulatory protein (BlxR) in Brucella. Microar-
ray analysis of a blxR mutant suggests that BlxR regulates the
expression of genes encoding the T4SS and ﬂagella. These results
were conﬁrmed by experimental evidence by deletion of blxR in B.
melitensis. Both BlxR and VjbR are positively auto-regulated and
cross-regulate the expression of each other (Rambow-Larsen et al.,
2008).
ANALYSIS OF BRUCELLA GENE EXPRESSION PROFILES
INSIDE HOST CELLS
The virulence of Brucella relies heavily on their ability to sur-
vive and replicate within the vacuolar phagocytic compartments
of macrophages (Baldwin and Winter, 1994; Roop et al., 2009).
After phagocytosis by macrophages, the brucellae reside within
a vacuole that interacts with early endosomes. These Brucella-
containing vacuoles (BCVs) avoid further interactions with the
endocytic pathway and interact with endoplasmic reticulum (ER).
After sustained interaction and fusion with the ER, mature BCVs
become replicative compartments (i.e., replicative phagosomes)
withER-like properties. This latematuration event (for thebiogen-
esis of an ER-derived replicative organelle) requires a functional
T4SS (Celli et al., 2003). Virulent brucellae successfully fuse with
ER cysternae and survive and multiply. However, attenuated bru-
cellae fail to fuse with ER and are destroyed inside of the host
phagolysosomes.
To investigate physiological adaptations of virulent Brucella
in its intracellular lifecycle, Lamontagne et al. (2009) infected
murine macrophages with virulent B. abortus 2308 or attenu-
ated B. abortus vaccine strain 19 and then compared the pro-
teomes of intracellular Brucella recovered at 3, 20, and 44 h after
macrophage infections. In total, 190 Brucella proteins were differ-
entially expressed in the time course of infections. Ninety Brucella
proteins were uniquely differentially expressed by strain 2308.
Thirty proteins were only differentially expressed by strain 19.
The remaining 70 proteins were differentially expressed by both
strains. In virulent strain 2308, carbohydrate based carbon uti-
lization and protein synthesis processes were initially reduced
when the cells switched to alternative energy sources and low
oxygen tension respiration. In the later stages of strain 2308
infection, the expressions of proteins related to key metabolic
processes, protein synthesis, iron acquisition, and transport were
signiﬁcantly up-regulated, and its cell envelope actively modi-
ﬁed. In contrast, strain 19 adjusted its metabolic proﬁle to a
lower degree in the early stage of infection. In the later stage
of infection, strain 19 was unable to revert to pre-infection
protein expression levels in key processes (Lamontagne et al.,
2009).
Al Dahouk et al. (2008) used a 2-D DIGE approach to charac-
terize the intramacrophagic proteome of B. suis at alate stage of
in vitro infection. Compared to extracellularly grown, stationary-
phase bacteria, the concentrations of 168 proteins were altered.
The majority of the 44 proteins differentially regulated at the
late stage of infection participated in bacterial metabolism. Of
these, 40% were down-regulated. These results indicate that
intramacrophagic B. suis has an adaptive response in terms of
quantitative reduction of processes involving energy, protein, and
nucleic acid metabolism.
Brucella infects hosts primarily by adhering and penetrating
mucosal epithelium surfaces. Similar to the kinetics proﬁle of Bru-
cella insidemacrophages, virulentBrucella have an initial adaption
period followed by a replicative phase inside epithelial cells. Using
cDNA microarray analysis, Rossetti et al. (2011) characterized the
transcriptional proﬁle of the intracellular pathogen B. melitensis
at 4 h (adaptation period) and at 12 h (replicative phase) following
infection of HeLa cells. The study found that 161 and 115 Brucella
genes were differentially expressed at 4 and 12 h, respectively, post
infection. Most of the genes expressed were involved in pathogen
growth and metabolism. At the adaptation period, 126 (78% of
161) genes were down-regulated. At the replicative phase, 86 (75%
of 115) genes were up-regulated.
MACROPHAGE IMMUNE RESPONSES TO BRUCELLA
INFECTIONS BASED ON OMICS GENE EXPRESSION DATA
ANALYSIS
The above section reviewed two proteomics and one transcrip-
tomics studies concerning proﬁling gene expression patterns of
different Brucella strain inside infected macrophages (Al Dahouk
et al., 2008; Lamontagne et al., 2009). DNAmicroarray analysis has
been used frequently to analyze transcriptomic gene expression
proﬁles in murine macrophages infected with virulent Brucella
strains (Eskra et al., 2003; He et al., 2006). Five studies on this
topic have been reported and summarized below.
Using Affymetrix murine U74A gene microarrays, Eskra et al.
(2003) found that over 140 genes, of the >6000 genes, were
reproducibly differentially transcribed in RAW264.7 macrophages
infected with B. abortus for 4 h. Initially, an increase in the
transcription of a number of proinﬂammatory cytokines and
chemokines, such as TNF-α, IL-1α, and IL-1β, was observed.
However, transcription of receptors and cytokines associated with
antigen presentation, e.g., MHC class II and IL-12p40, were not
found at 4 h post infection. Virulent B. melitensis also inhibited
transcription of various host genes involved in apoptosis and
intracellular vesicular trafﬁcking. It appears that Brucella utilizes
speciﬁc mechanisms to inhibit many cell pathways (Eskra et al.,
2003).
Covert et al. (2009) subsequently demonstrated that the infec-
tions with B. melitensis, B. neotomae, and B. ovis bacteria for 4 h
elicit common and distinctive defense transcriptional responses
of RAW 264.7 macrophages. Although few B. melitensis and B.
neotomae cells enter macrophages,B. ovis cells are readily ingested
by macrophages. Macrophages infected with these different Bru-
cella species demonstrated common changes in gene expres-
sion compared to uninfected macrophages. Compared to unin-
fected macrophages,macrophage infections with all three Brucella
species induced increased transcript levels of 72 genes including
chemokines and defense response genes (e.g., IL-1β, MIP-1α, Fas,
and TNF). Meanwhile, decreased transcript levels of 68 genes,
such as genes associated with vesicular trafﬁcking (e.g., Rab3d)
and response to external stimulus (e.g., IL-17a), were identiﬁed in
macrophages infected with all three Brucella species. Genes with
altered transcript levels of Brucella-infectedmacrophagesmay cor-
relate with Brucella species-speciﬁc host defenses and intracellular
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survival strategies. B. melitensis, but not B. neotomae or B. ovis,
is pathogenic to human. Correspondingly, the infection with B.
melitensis, but the other two Brucella spp., induced decreased gene
expression in growth arrest (Gas2), immunoglobulin receptor (Fc
gamma RI), and chemokine receptor (Cxcr4) genes (Covert et al.,
2009).
He et al. (2006) analyzed the time course response of J774.A1
macrophages during infection with virulent B. melitensis strain
16M using Affymetrix mouse 430 2.0 array containing more than
39,000 genes. Transcriptions of 243 up-regulated and 1053 down-
regulated genes were identiﬁed at 4 h post infection compared
to uninfected macrophages. However, compared to uninfected
macrophages, only 12 genes were found up- or down-regulated
after 24 h, and no genes were found differentially regulated at
48 h post infection. Although many pro-apoptosis genes were up-
regulated, it is noteworthy that the caspase cascade pathways were
not activated. These results suggest that some upstream compo-
nent(s) that induces caspase activation is suppressed. Interestingly,
caspase-2, a caspase that regulates the release of cytochrome c
from the mitochondria, was down-regulated. Furthermore, 106
mitochondria-associated genes were down-regulated while only
4 mitochondria-associated genes were up-regulated at 4 h post
infection (He et al., 2006). It seems that B. melitensis 16M may
prevent apoptosis in macrophages by suppressing mitochondr-
ial gene expression involved in cytochrome c release, reactive
oxygen species (ROS) production, and mitochondrial membrane
permeability, thereby preventing activation of caspase cascades.
Prevention of apoptosis in macrophages by B. melitensis strain
16M ensures extensive replication after the initial killing stage.
Such inhibition may contribute to the ability of Brucella spp. to
persist chronically in the reticuloendothelial system of infected
humans and animals. Many of the hypotheses generated from the
microarray analyses were later conﬁrmed by other studies (Chen
andHe, 2009; Chen et al., 2011). For example,wet-lab experiments
from the same group found that smoothB. abortus strain 2308pre-
vents mitochondrial permeability and the release of cytochrome
c from mitochondria. Smooth virulent Brucella strains that con-
tain intact LPS are capable of inhibiting programmed cell death
in infected human and mouse macrophages (Gross et al., 2000;
Tolomeo et al., 2003; He et al., 2006). Rough attenuated Brucella
strains, which lack O-antigen or produce extremely low levels of
the antigen, cannot survive inside macrophages and indeed induce
programmed cell death (Fernandez-Prada et al., 2003; Rittig et al.,
2003; Pei and Ficht, 2004). The author’s laboratory found that
rough and live attenuated B. abortus strains RB51 (the current
cattle vaccine) and RA1 induced a caspase-2-mediated apoptotic
and necrotic macrophage cell death (Chen and He, 2009). An
inhibition of caspase-2 prevents cytochrome c release and almost
completely inhibited cell death induced by these rough strains.
Brucella suis primarily infects pigs and is pathogenic to humans.
Our studies reveal that smooth virulent B. suis strain 1330 (S1330)
prevents programmed cell death of infected macrophages. How-
ever, rough attenuated B. suis strain VTRS1 (a vaccine candidate)
induces a high level of macrophage cell death. Like B. abortus
vaccine strain RB51, VTRS1 has a Brucella wboA gene mutation,
which results in the deﬁciency of LPS O-antigen as well as the
rough phenotype (Winter et al., 1996). An Affymetrix microarray
studywas conducted to analyze temporal transcriptional responses
of murine macrophage-like J774.A1 cells infected with S1330
or VTRS1, 17,685 probe sets were signiﬁcantly up- or down-
regulated depending on Brucella strain, time, and the interaction
between the strain and time (Chen et al., 2011). A miniTUBA
dynamic Bayesian network analysis predicted thatVTRS1-induced
macrophage cell death was mediated by a proinﬂammatory gene
TNF-α, an NF-κB pathway gene IκB-α, and caspase-2. Compared
to S1330, VTRS1-induced a dramatically higher level of proin-
ﬂammatory response as indicated by increased transcriptions of
40 proinﬂammatory genes. Increased protein level production of
TNF-α and IL-1β were detected in the supernatants in VTRS1-
infected macrophage cell culture. Inhibition and knockout mouse
studies further conﬁrmed thatVTRS1 induces a proinﬂammatory,
caspase-2- and NF-κB-mediated macrophage cell death. Interest-
ingly, caspase-1 does not play any obvious role in the VTRS1-
induced macrophage cell death in studies utilizing a caspase-
1 inhibitor (Chen et al., 2011). This novel caspase-2-mediated
proinﬂammatory cell death differs from apoptosis (which is not
proinﬂammatory), and differs from classical caspase-1-mediated
pyroptosis. The details of themechanism for the cell death pathway
and the biological relevance of this pathway in Brucella pathogen-
esis and protective Brucella immunity are currently under active
investigations.
Using a cDNA microarray technology, Rossetti et al.
(2010) compared the early transcriptome of B. abortus-infected
monocyte-derived macrophages (MDMs) from cattle naturally
resistant (R) or susceptible (S) to brucellosis. The MDMs isolated
fromperipheral bloodwere infectedwith virulentB. abortus strain
2308 for 24 h. Their study identiﬁed slightly increased genome
activation in R MDMs and a down-regulated transcriptome in S
MDMs. Speciﬁcally, compared to uninfected cells, Brucella infec-
tion induced 46 up- and 195 down-regulated genes in S MDMs
at 12 h post infection. In R MDMs, 31 genes were up- and 25
genes were down-regulated at 12 h postinfection. R MDMs had
the ability to induce a type 1 immune response against B. abortus
infection, including up-regulation of CCL4 and reduced expres-
sion of EBF1. This ability was impaired in S cells, as demonstrated
by decreased expression of HSPA14, TCIRG1, and C1QBP genes.
Several inﬂammation-associated host genes, such as IL-1A, CCL2,
and CCL5, were up-regulated in infected S MDMs. These differ-
ences may explain the different resistances of MDMs to virulent
Brucella infection.
HOST EPITHELIAL CELL RESPONSES TO BRUCELLA
INFECTIONS BASED ON OMICS GENE EXPRESSION DATA
ANALYSIS
Brucella abortus induces acute placentitis and abortion in infected
animals, key events for transmission of the disease. To better
understand the intricate interaction between B. abortus and tro-
phoblastic cells, Carvalho Neta et al. (2008) evaluated the proﬁle
of gene expression by bovine trophoblastic cells during infection
with B. abortus. Microarray analysis was performed after explants
of chorioallantoic membranes were infected with B. abortus strain
2308 for 4 h. Expression of proinﬂammatory genes by trophoblas-
tic cells was suppressed at 4 h after inoculation. A signiﬁcant
up-regulation of CXC chemokines [CXCL6 (GCP-2) and CXCL8
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(interleukin 8)] was observed at 12 (but not at 6 h) after inocu-
lation. Therefore, in trophoblastic cells infected with virulent B.
abortus, the expression of proinﬂammatory mediators was sup-
pressed during the early stages of infection. This was followed by
a delayed and mild expression of proinﬂammatory chemokines. A
similar proﬁle of chemokine expression, including up-regulation
of CXCL6 and CXCL8, was found in the placentomes of experi-
mentally infected cows. The kinetic trophoblastic response is likely
to contribute to the pathogenesis of B. abortus-induced placentitis
(Carvalho Neta et al., 2008).
INNATE HOST SPLENOCYTE RESPONSES TO BRUCELLA
INFECTIONS BASED ON DNA MICROARRAY ANALYSES
Soon after Brucella cells invade a host, infectious brucellae migrate
to the spleen and liver. In spleen and liver, the course of Brucella
infection encompasses four phases. The early preimmune infec-
tion phase is characterized by logarithmic Brucella growth and an
accumulation of bacteria in the liver and spleen. The second bacte-
riostatic phase is typically accompaniedwith the onset of a delayed
type hypersensitivity to Brucella antigens and granuloma forma-
tion. In the third immune effector phase, up to 90% of the bacteria
may be destroyed. This phase is typically followed by a phase of
obviously impaired eradication of bacteria (phase IV; Hort et al.,
2003).
Spleen is most frequently used for analysis of innate and adap-
tive immune responses to Brucella infections. To identify host
responses speciﬁcally regulated by the Brucella T4SS, Roux et al.
(2007) used Affymetrix mouse 430 2.0 arrays to compare early
transcriptional responses of mouse splenocytes to infection with
B. abortus, B. melitensis, and B. abortus virB mutants defective
in the T4SS. The largest number of differentially expressed genes
occurred in the categories of inﬂammation and immunity.Galindo
et al. (2010) studied gene expression changes in spleens of the
wildlife reservoir species Eurasian wild boar (Sus scrofa), which is
naturally infected with B. suis biovar 2. B. suis biovars (bv.) 2 is
frequently isolated from wild boar and hares and largely restricted
to Europe. This study identiﬁed 633 up-regulated genes and 1373
down-regulated genes in infected wild boar. B. suis bv. 2 infec-
tion induced up-regulation of genes in cell maturation,migration,
and/or proliferation in infected animals. The down-regulated
genes are associated with impaired activity of several important
cellular metabolic pathways including metabolism, cytoskeleton
organization and biogenesis, stress, apoptosis, immune response
and lysosomal function, and vesicle-mediated transport. These
gene expression proﬁles facilitate intracellular multiplication and
the development of chronic infections.
ANALYSIS OF HOST BLOOD CELL IMMUNE RESPONSES TO
BRUCELLA VACCINATION AND CHALLENGE USING
MICROARRAY TECHNOLOGY
Brucella ovis causes ovine brucellosis, characterized by infertility in
rams, abortion in ewes, and increased perinatalmortality in lambs.
Galindo et al. (2009a) characterized differential transcriptomics
gene expression in buffy coat samples of rams experimentally
infected with B. ovis strain PA by microarray hybridization and
real-time RT-PCR. The buffy coat, the fraction of an anticoagu-
lated blood sample after density gradient centrifugation, contains
most of the white blood cells and platelets. Of the 600 ruminant
inﬂammatory and immune response genes, 20 and 14 genes in the
buffy coat samples were signiﬁcantly regulated, with an expres-
sion fold change >1.75 with a P-value< 0.05, at 15 and 60 days
post-challenge (dpc), respectively. Speciﬁcally, in infected rams
at 15 dpc, 16 were up-regulated, and 4 were down-regulated. At
60 dpc, 11 and 3 genes, respectively, were up- and down-regulated
in infected rams. Four genes, desmoglein, ENaC-alpha, IL18BP,
and MIF, were up-regulated at both 15 and 60 dpc. The inﬂam-
matory and innate immune pathways were activated in infected
animals. The infection of B. ovis up-regulated phagocytosis-
associated genes and down-regulated genes related to protective
host defense. These responses facilitate the chronicity of B. ovis
infection.
Omics can also be used to characterize possible correlates of
protective response against Brucella infection. Vaccination with
live attenuated B. melitensis Rev 1 vaccine is used to control
ovine brucellosis caused by B. ovis in sheep. To identify possi-
ble correlates of protective response to B. ovis infection, Galindo
et al. (2009b) used microarrays to characterize inﬂammatory and
immune response genes differentially expressed in ramspreviously
immunized with Rev 1 and experimentally challenged with B. ovis.
Total RNAwas isolated frombuffy coat samples before vaccination
(T0), 150 days after vaccination and before challenge (T1), and
60 dpc (T2). Protected and susceptible rams did not show signiﬁ-
cant differences in gene expression prior to vaccination with Rev 1
(timeT0). After vaccination, but prior to challenge (T1), the toll-
like receptor 10 (TLR10) was the only gene signiﬁcantly expressed
at higher levels in protected rams as compared to vaccinated rams
that were susceptible toB. ovis infection. Concomitantly, 12 proin-
ﬂammatory and innate immune effectors were up-regulated in
vaccinated rams that were susceptible to B. ovis infection. After
challenge with B. ovis at time T2, the vaccinated and protected
rams showed higher expression levels of Bcl-2-homologous antag-
onist/killer (Bak), annexin I (ANXI), and interleukin 6 (IL6) genes.
These genes provide possible correlates of protective response to
B. ovis infection in rams immunized with Rev 1 vaccine.
ANALYSIS OF BRUCELLA-SPECIFIC SEROLOGICAL ANTIBODY
RESPONSES USING PROTEOMICS
Protein expression in bacteria is an important determinant in
the induction of Brucella-speciﬁc antibodies. A systems biology
approach can be used to identify antibody signatures associated
with Brucella infections in humans and to predict serodiagnostic
antigens. Using a full proteomemicroarray expressing 3046 cloned
B.melitensis genes,Liang et al. (2011) identiﬁed 122 immunodom-
inant antigens and 33 serodiagnostic antigens. The reactive anti-
gens had enriched features in terms of membrane association and
secretion as indicated by the presence of a signal peptide, a single
transmembrane domain, and an outer membrane or periplasmic
location. This systems biology approach facilitates the understand-
ing of the breadth and speciﬁcity of the immune response to B.
melitensis.
In clinical settings, the detection of agglutinating anti-LPS anti-
bodies is the basis for current serological diagnosis of human
brucellosis. To better understand the multiplicity of antibody
responses that develop after B. melitensis infection, Liang et al.
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(2010) used a protein microarray containing 1406 predicted B.
melitensis proteins to analyze sera from experimentally infected
goats and naturally infected humans from an endemic region in
Peru. Eighteen antigens were differentially recognized by infected
and non-infected goats. Thirteen serodiagnostic antigens were
identiﬁed that differentiated humanpatientswith acute brucellosis
from syndromically similar patients. Only two of the serodiagnos-
tic antigens overlapped between humans and goats. A number of
cross-reactive antigens were found in healthy goats and healthy
humans (Liang et al., 2010). This study demonstrates that an
experimentally infected natural reservoir host and a naturally
infected human host produce different immune responses.
BRUCELLA VACCINE TARGET PREDICTION BASED ON
GENOME SEQUENCE ANALYSIS USING VAXIGN REVERSE
VACCINOLOGY
Reverse vaccinology is an emerging and revolutionary vaccine
development strategy that starts with the prediction of vaccine
targets by bioinformatics analysis of genome sequences (Rappuoli,
2000; He et al., 2010a). Reverse vaccinology was ﬁrst applied in the
development of a vaccine against serogroup B Neisseria menin-
gitidis (MenB; Pizza et al., 2000). The complete MenB genome
was screened for genes coding for putative surface-exposed and
secreted proteins. Out of∼600 novel vaccine candidates, 350 were
expressed in Escherichia coli; 28 were found to elicit protective
immunity (Pizza et al., 2000). Reverse vaccinology has also been
applied successfully to other pathogens such as Streptococcus pneu-
moniae, Porphyromonas gingivalis, and Chlamydia pneumoniae
(Rappuoli, 2000).
To promote vaccine development, the author’s laboratory
has developed Vaxign2, the ﬁrst web-based vaccine design pro-
gram based on reverse vaccinology (Xiang and He, 2009; He
and Xiang, 2010; He et al., 2010b). Predicted features in the
Vaxign pipeline include protein subcellular location, transmem-
brane helices, adhesin probability, sequence conservation among
genomes of pathogenic strains, exclusion of sequences in non-
pathogenic strains, exclusion of proteins shared in host spp. (e.g.,
human, mouse, and pigs), and epitope binding to MHC class I
and class II. Currently more than 200 genomes have been pre-
computed using the Vaxign pipeline. The results are available for
query in the Vaxign website. Vaxign also allows dynamic vaccine
target prediction based on protein sequences provided by users. A
user can register for a private account inVaxign and save predicted
results for further analyses.
Based on the Vaxign reverse vaccinology approach, sequenced
Brucella genomes have been used for predicting vaccine targets
for Brucella spp. (Xiang and He, 2009; He and Xiang, 2010). An
O-sialoglycoprotein endopeptidase was predicted to be a secreted
Brucella protein.Among 3034proteins inB. abortus strain 2308,32
were identiﬁed as OMPs. Two of the 32 OMPs contain more than
one transmembrane alpha-helixes. Twenty out of the remaining 30
proteins are predicted as adhesins or adhesin-like proteins. Fifteen
of these 20 OMPs are conserved in pathogenic B. abortus, B. suis,
and B. melitensis strains. One of the 15 proteins is homologous
2http://www.violinet.org/vaxign
to a human protein. Among the ﬁnal 14 proteins are two known
Brucella protective antigens (Omp25 and Omp31-1), two ﬂagellar
hookproteins FlgE andFlgK,oneporinproteinOmp2b, twoTonB-
dependent receptor proteins. Omp2b and Omp31-1 are absent
from the genome of B. ovis, a Brucella species non-pathogenic
to human (He and Xiang, 2010). The feasibility of using these
Brucella proteins for development of a safe and effective human
vaccine deserves further investigation.
LITERATURE MINING OF BRUCELLA VIRULENCE FACTORS
AND PATHOGENESIS NETWORK
Many virulence factors have been retrieved by literature mining of
all Brucella publications found in PubMed. Seventy-ﬁve mutated
Brucella genes were identiﬁed to be attenuated insidemacrophages
or HeLa cells, or in an in vivo mouse model, using a litera-
ture mining and curation system (Limix) as part of the Brucella
Bioinformatics Portal (BBP; Xiang et al., 2006). These 75 mutated
Brucella genes are essential for Brucella virulence and pathogene-
sis and are thus treated as Brucella virulence factors (Xiang et al.,
2006). Basedon theNCBIClusters of OrthologousGroups (COGs;
Tatusov et al., 2000), the 75 Brucella genes have been classiﬁed into
different categories. This study conﬁrms the well-known patho-
genesis mechanisms of Brucella T4SS encoded by the virB operon
(O’Callaghan et al., 1999), the BvrR–BvrS two-component regu-
latory system encoded by bvrR and bvrS (Sola-Landa et al., 1998),
and the intact Brucella lipopolysaccharide (Allen et al., 1998). The
curation demonstrated an important role of the transport and
metabolismof variousmetabolites including amino acid, carbohy-
drate, lipid, and inorganic ions. Those Brucella genes participating
in these events are essential for intracellular Brucella growth and
their survival inside phagosomes of eukaryotic cells.
The updated BBP database contains 181 Brucella virulence
factors. These are classiﬁed by the mutants’ attenuated charac-
teristics in host cells or in animals in vivo (Table 2). A new statistic
COG analysis of these virulence factors conﬁrmsmany of previous
data mining results. Six COG categories are signiﬁcantly enriched
(P-value< 0.05), including: (i) Nucleotide transport and metab-
olism (COG category F), (ii) Cell motility (COG category N), (iii)
Translation (COG category J), (iv) Carbohydrate transport and
metabolism (COG category G), (v) General function prediction
(COG category R), and (vi) Function unknown (COG category S;
Table 2). Beside these groups, many other categories, such as Sig-
nal transduction mechanisms (COG category T) and Intracellular
trafﬁcking and secretion (COG category U), are also critical for
Brucella pathogenesis. These factors may not be crucial for Bru-
cella survival in vitro.However, their presence is critical forBrucella
replication in vivo. Many Brucella virulent factors have no deﬁned
functions and are classiﬁed in the categories of General function
prediction,Functionunknown,orNot inCOGs.How these factors
become virulence factors deserves further investigations.
Literature mining approaches can also be used to identify
genetic networks crucial for Brucella pathogenesis. Out of 1358
potential interactions available from more than 7000 abstracts
and/or full text papers extracted from PubMed, the Limix sys-
tem found 69 true positive interactions (Xiang et al., 2006). These
interactions were automatically displayed using our graphic visu-
alization program. These results allow a more comprehensive
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Table 2 | Brucella virulence factors classified by their mutants’ attenuation.
No. Gene name Locus tag Attenuation Reference (PMID)*
COG CATEGORY C: ENERGY PRODUCTIONAND CONVERSION
1 cydB BMEII0759 Mice 11274104
2 fdhA BMEII0378 Mice 14979322
3 glpK BMEII0823 Mice, macrophages, HeLa 14979322
4 narG BMEII0950 Macrophages 12438693
5 norE BMEII1001 Mice 14979322
6 pyc BMEI0266 Macrophages 10678941
D: CELL CYCLE CONTROL, MITOSIS, AND MEIOSIS
7 virB5 BMEII0029 Macrophages 10510235
E:AMINOACIDTRANSPORTAND METABOLISM
8 aroC BMEI1506 Macrophages, HeLa, mice 11119550
9 aspC BMEI0516 HeLa 12761078
10 BMEII0626 BMEII0626 Mice, macrophages, HeLa 14979322
11 BMEII0923 BMEII0923 Mice 14979322
12 cysK BMEI0933 Mice, macrophages, HeLa 14979322
13 dppA BMEI0433 Mice, macrophages, HeLa 14979322
14 glnA BMEI0979 Macrophages 12438693
15 gltD BMEII0040 Mice 10858227
16 glyA BMEI1192 Macrophages 12438693
17 hisD BMEI1668 Macrophages 12438693
18 hisF BMEI2041 Macrophages 12438693
19 leuA BMEI0451 Macrophages 12438693
20 leuC BMEI0157 Macrophages 12438693
21 lysA BMEI0084 Macrophages 12438693
22 metH BMEI1759 Mice, macrophages, HeLa 14979322
23 nifS BMEI1043 Macrophages 14979322
24 pheB BMEII0136 Mice 14979322
25 serB BMEI0615 Macrophages 12438693
26 thrA BMEI0725 Macrophages 14979322
27 thrC BMEI1450 Macrophages 14979322
F: NUCLEOTIDETRANSPORTAND METABOLISM**
28 carAB BMEI0526 Macrophages 14979322
29 dut BMEI0358 Macrophages 12438693
30 hpt BMEI0082 Macrophages, HeLa 14979322
31 ndrI BMEII0931 HeLa 14979322
32 purD BMEI1519 Mice, macrophages 15271960
33 purE BMEI0296 Mice 15271960
34 purF BMEI1488 HeLa 12761078
35 purH BMEI0233 Mice, macrophages 15271960
36 purL BMEI1127 Macrophage, mice 15271960
37 purM BMEI1240 HeLa 12761078
38 purN BMEI1241 HeLa 12761078
39 pyrB BMEII0670 HeLa 12761078
40 pyrC BMEII0669 Macrophages, HeLa 14979322
41 pyrD BMEI1611 HeLa 12761078
G: CARBOHYDRATETRANSPORTAND METABOLISM**
42 BMEII1045 BMEII1045 Mice, macrophages, HeLa 14979322
43 cbbE BMEI1116 Macrophages, HeLa 14979322
44 dbsA BMEII0300 HeLa 14979322
45 eryC BMEII0428 Mice, macrophages 16177356
46 galcD BMEII0485 Mice, macrophages, HeLa 14979322
47 gluP BMEII1053 Mice 12414147
(Continued)
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Table 2 | Continued
No. Gene name Locus tag Attenuation Reference (PMID)*
48 gnd BMEII1124 Mice 12761078
49 ilvD BMEI1848 Mice, macrophages 15271960
50 malK BMEI1713 Macrophages 14979322
51 manB BMEII0899 Mice, macrophages, HeLa 14979322
52 mocC BMEII0570 Mice, HeLa 14979322
53 ndvB BMEI1837 Mice, HeLa 14979322
54 pgi BMEI1636 Macrophages 10678941
55 pgm BMEI1886 Mice 12525425
56 pmm BMEI1396 Mice, macrophages, HeLa 14979322
57 rbsK BMEII0089 Macrophages 14979322
58 ugpA BMEII0624 Mice 14638795
59 xfp BMEII0881 Mice, macrophages, HeLa 14979322
60 zwf BMEII0513 HeLa, macrophages 12761078
H: COENZYMETRANSPORTAND METABOLISM
61 BMEI1902 BMEI1902 Mice, macrophages, HeLa 14979322
62 caiB BMEI1019 Macrophages 14979322
63 cobB BMEI0705 Mice 14638795
64 hemH BMEII0018 Mice, macrophages, HeLa 11553564
65 ilvC BMEI0624 Mice 14638795
66 ilvI BMEI0617 Macrophages, HeLa 14979322
I: LIPIDTRANSPORTAND METABOLISM
67 aidB BMEII0671 Macrophages 14979322
68 bacA BMEI1553 Mice, macrophages 10741969
69 uppS BMEI0827 Macrophages 12438693
J:TRANSLATION**
70 miaA BMEI0616 Macrophages 12438693
71 rpsA BMEI1915 Macrophages 10678941
K:TRANSCRIPTION
72 ansC BMEI0357 Mice, macrophages, HeLa 14979322
73 arsR6 BMEI0430 Mice 16113274
74 aspB BMEI0626 Macrophages 14979322
75 deoR BMEII1093 Macrophages 14979322
76 gntR BMEII1066 Macrophages, HeLa 14979322
77 gntR1 BMEII0475 Mice 16113274
78 gntR10 BMEII0116 Mice 16113274
79 gntR17 BMEI0320 Mice 16113274
80 gntR2 BMEI0305 Mice 16113274
81 gntR4 BMEI0169 Mice 16113274
82 gntR5 BMEI0881 Mice 16113274
83 lysR BMEI0513 Macrophages, HeLa 14979322
84 lysR12 BMEII0390 Mice 16113274
85 lysR13 BMEI1913 Mice 16113274
86 lysR18 BMEI1573 Mice 16113274
87 rho BMEI0003 HeLa 11579087
88 RpiR BMEII0573 Mice 14979322
89 rpoA BMEI0781 Mice 14638795
90 vjbR BMEII1116 Mice, macrophages, HeLa 14979322
L: REPLICATION, RECOMBINATION,AND REPAIR
91 alkA BMEI0382 Mice, macrophages, HeLa 14979322
92 BMEI1229 BMEI1229 Mice, macrophages, HeLa 14979322
93 mgps BMEI0275 Mice, macrophages, HeLa 14979322
94 recA BMEI0787 Mice 8321120
(Continued)
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Table 2 | Continued
No. Gene name Locus tag Attenuation Reference (PMID)*
95 xerD BMEI0040 Mice, macrophages 15519045
96 xseA BMEII0527 Mice 14638795
M: CELLWALL/MEMBRANE BIOGENESIS
97 amiC BMEI1056 Macrophages, HeLa 14979322
98 galE BMEI1237 Macrophages, HeLa 14979322
99 gtrB BMEII1101 Macrophages 14979322
100 lpsA BMEI1326 Macrophages 14979322
101 lpsB BMEI0509 Macrophages 14979322
102 macA BMEI0359 Mice, macrophages, HeLa 14979322
103 mtgA BMEI0271 Mice 15519045
104 omp25 BMEI1249 Mice, cattle, goats 15374004
105 perA BMEI1414 Macrophages 14979322
106 rfbD BMEI1413 Mice, macrophages 14979322
107 wbdA BMEI0997 Macrophages 14979322
108 wbkA BMEI1404 Mice 14979322
109 wbpL BMEI1426 Mice, macrophages 14979322
110 wbpW BMEII0900 Macrophages 14979322
111 wbpZ BMEI1393 Mice, macrophages 14979322
N: CELL MOTILITY**
112 ﬂgE BMEII0159 Mice 14979322
113 ﬂgI BMEII1084 Mice 14979322
114 ﬂiC BMEII0150 Mice 14979322
115 motB BMEII0154 Mice 14979322
O: POSTTRANSLATIONAL MODIFICATION, PROTEINTURNOVER, CHAPERONES
116 BMEI0455 BMEI0455 Mice, macrophages, HeLa 14979322
117 cydC BMEII0761 Macrophages, HeLa 14979322
118 cydD BMEII0762 HeLa 12761078
119 cysY BMEI1849 Macrophages, HeLa 14979322
120 dnaK BMEI2002 Macrophage 11854256
121 dsbA BMEI1440 Macrophages, HeLa 14979322
122 dsbB BMEI0384 Mice, macrophages 14979322
123 glnD BMEI1804 Macrophages, HeLa 10678941
124 htrA BMEI1330 Mice, neutraphils, macrophages 8890248
125 lon BMEI0876 Mice 10672180
126 nrdH BMEII0932 HeLa 14979322
127 ppiD BMEI0845 Mice, macrophages, HeLa 14979322
128 tig BMEI1069 Mice 14638795
P: INORGANIC IONTRANSPORTAND METABOLISM
129 BMEII0336 BMEII0336 Mice, macrophages, HeLa 14979322
130 cysI BMEI1766 Mice, macrophages 14979322
131 mgtB BMEII0056 Mice, macrophages, HeLa 14979322
132 sodC BMEII0581 Macrophage, mice 15845493
133 znuA BMEII0178 HeLa, macrophages 15472468
134 znuC BMEII0177 Macrophages, HeLa 14979322
Q: SECONDARY METABOLITES BIOSYNTHESIS,TRANSPORT,AND CATABOLISM
135 dhbC BMEII0077 Pregnant goat 14979322
T: SIGNALTRANSDUCTION MECHANISMS
136 BMEI1448 BMEI1448 Mice, macrophages, HeLa 14979322
137 bvrR BMEI2036 Mice, macrophages, HeLa 16077108
138 bvrS BMEI2035 Mice, macrophages, HeLa 16077108
139 divK BMEII0659 Mice 14979322
140 feuP BMEI1337 Mice, macrophages 14979322
(Continued)
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Table 2 | Continued
No. Gene name Locus tag Attenuation Reference (PMID)*
141 feuQ BMEI1336 Mice, macrophages, HeLa 14979322
142 ftcR BMEII0158 Mice 17056750
143 glnL BMEI1786 Macrophages 14979322
144 nodV BMEII0052 Mice, macrophages, HeLa 14979322
145 ntrY BMEI0867 Mice 10678941
146 pstP BMEI0190 Macrophages, HeLa 14979322
147 spotT BMEI1296 Macrophages, HeLa 14979322
148 vsrB BMEI1606 Mice, macrophages, HeLa 14979322
U: INTRACELLULARTRAFFICKINGAND SECRETION
149 ﬂghA BMEII0166 Mice 14979322
150 ﬂiF BMEII0151 Mice 14638795
151 virB3 BMEII0027 HeLa 12761078
152 virB2 BMEII0026 Macrophages, mice 15322008
153 virB8 BMEII0032 Macrophage 10678941
V: DEFENSE MECHANISMS
154 BMEII0318 BMEII0318 Mice, macrophages, HeLa 14979322
155 dacF BMEII0350 Macrophages, HeLa 14979322
156 exsA BMEI1742 Mice 14979322
R: GENERAL FUNCTION PREDICTION ONLY**
157 bicA BMEI0605 Macrophages 14979322
158 BMEI0671 BMEI0671 Macrophages 14979322
159 BMEI1443 BMEI1443 Mice, macrophages, HeLa 14979322
160 BMEI1531 BMEI1531 Mice, macrophages, HeLa 14979322
161 BMEI1859 BMEI1859 Macrophages 14979322
162 BMEII0274 BMEII0274 Macrophages 14979322
163 BMEII0935 BMEII0935 Mice, macrophages, HeLa 14979322
164 BMEII1037 BMEII1037 Mice 14979322
165 cobW BMEII0308 Macrophages 12438693
166 glt1 BMEII0039 Mice 14979322
167 hfq BMEI0872 Macrophage, mice 12730323
168 mosC BMEI0267 Mice 14979322
169 rbsC BMEII0701 Mice, macrophages, HeLa 14979322
170 tldD BMEI1468 Mice 14979322
S: FUNCTION UNKNOWN**
171 BMEI1809 BMEI1809 Mice, macrophages, HeLa 14979322
172 BMEII0128 BMEII0128 Mice, macrophages, HeLa 14979322
173 pncA BMEI0545 Mice, macrophages, HeLa 15135535
NOT IN COGs
174 BMEI0085 BMEI0085 Macrophages 14979322
175 BMEI1339 BMEI1339 Mice, macrophages, HeLa 14979322
176 BMEI1361 BMEI1361 Mice 14979322
177 BMEI1658 BMEI1658 Macrophages 14979322
178 BMEI1844 BMEI1844 Mice, macrophages, HeLa 14979322
179 BMEI1879 BMEI1879 Mice, macrophages, HeLa 14979322
180 omp10 BMEII0017 Mice 12228280
181 omp19 BMEI0135 Mice 12228280
*Each reference is indicated by PubMed citation ID (i.e., PMID). **Signiﬁcantly enriched COG category based on Fisher’s exact test (P-value<0.05).
investigation of Brucella pathogenesis and the generation of novel
hypotheses (Xiang et al., 2006). For example, this study iden-
tiﬁed a possible interaction between T4SS and the BvrR–BvrS
two-component regulatory system. Speciﬁcally, the secretion of
the N-terminal fragment of BvrR fused to a ribosome binding
site and start codon deﬁcient chloramphenicol acetyl transferase
(CAT) report gene is diminished in virB1 and virB10 mutants
(Marchesini et al., 2004). How the T4SS regulates the BvrR/BvrS
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system remains unclear. However, Martinez-Nunez et al. (2010)
recently found that BvrR/BvrS regulates the expression of the T4SS
VirB in B. abortus.
As described below, biomedical ontologies can be used to
dramatically improve Brucella literature mining.
ONTOLOGY-BASED ANALYSIS OF BRUCELLA
PATHOGENESIS, HOST IMMUNITY, AND VACCINE TARGETS
A biomedical ontology is a consensus-based, controlled vocabu-
lary of terms and relations, with associated deﬁnitions that are
logically formulated in such a way as to promote automated rea-
soning (Xiang et al., 2010). Biomedical ontologies structure and
interlink knowledge and data from complex biomedical domains
in such a fashion as to permit shared understanding of a speciﬁc
domain among different resources.
Extensive brucellosis research has resulted in a large number of
publications encompassing various medical topics ranging from
basic Brucella genetic study to vaccine clinical trials. To support
data exchange and reasoning, a Brucellosis Ontology (IDOBRU)3
has been developed (Lin et al., 2011). IDOBRU is a biomedical
ontology in the brucellosis domain and is an extension ontology of
the core infectious disease ontology (IDO-core; Cowell and Smith,
2010). Currently IDOBRU contains more than 1000 ontology
terms covering areas such as etiology, transmission, symptoms,vir-
ulence factors, pathogenesis, prevention, and treatment. IDOBRU
has been used to model different aspects of brucellosis, includ-
ing host infection and zoonotic disease transmission, symptoms,
virulence factors and pathogenesis, diagnosis, intentional release,
vaccine prevention, and treatment. IDOBRU is the ﬁrst reported
bacterial IDO that has been developed to model different disease
aspects in a formal logical format (Lin et al., 2011). The ontol-
ogy can serve as a knowledgebase for Brucella and brucellosis.
IDOBRU captures the knowledge extracted from published peer-
reviewed sources that cover brucellosis bench research, clinical
practice, and public health. In addition, IDOBRU has stored all
Brucella virulence factors discussed in BBP (Table 2).
The vaccine ontology (VO)4 is an open-access community-
supported ontology in the domain of vaccine and vaccination
(He et al., 2009). VO represents various vaccines and their rela-
tions. VO has collected more than 40 curated Brucella vaccines
or vaccine candidates that have been ofﬁcially licensed or proven
to provide protection in animal models. The ontology provides
detailed machine-readable information for each Brucella vaccine,
such as the vaccine type, manufacturers of licensed vaccines, and
host immune responses. Fourteen protective Brucella antigens
have been included in VO. In addition, VO has been used to inte-
grate many other vaccine data in theVIOLIN vaccine database and
analysis system5 (Xiang et al., 2008).
IDOBRU and VO can be used to support Brucella and brucel-
losis data exchange, data integration, and automated reasoning.
These two ontologies use a machine-readable Web ontology lan-




reasoning. Software programs can be developed to query IDO-
BRU and VO and to perform statistical and reasoning analyses.
One particular research area of note is the application of these
ontologies to advanced literature mining. In PubMed vaccine lit-
erature indexing is poorly performed due to limited hierarchy
of Medical Subject Headings (MeSH) annotation in the vaccine
ﬁeld. SciMiner is a literaturemining system that supports literature
indexing and gene name tagging (Hur et al., 2009). Our study indi-
cates that application of VO in SciMiner will aid vaccine literature
indexing and mining of vaccine–gene interaction networks. Using
the abstracts of 14,947Brucella-related papers,VO-SciMiner iden-
tiﬁed 140 Brucella genes associated with Brucella vaccines. These
genes included known protective antigens, virulence factors, and
genes closely related to Brucella vaccines. When a total of 67 Bru-
cella vaccine terms were incorporated into theVO-based SciMiner
(VO-SciMiner), the program exhibited a superior performance
in retrieving Brucella vaccine-related papers over that obtained
with a MeSH-based PubMed literature search. For example, a VO-
SciMiner search of “live attenuated Brucella vaccine” returned 922
hits as of April 20, 2011, while a PubMed search of the same query
yielded only 74 (Hur et al., 2011). VO has identiﬁed 17 live atten-
uated Brucella vaccines (Hur et al., 2011). Licensed live attenuated
vaccines RB51, strain 19, and Rev. 1 have been tested in mouse
and large animals. Many live attenuated Brucella vaccines at the
research stage have recently been tested in relevant animal mod-
els. For example,microencapsulated RB51 (Arenas-Gamboa et al.,
2009a) and strain 19 (Arenas-Gamboa et al., 2009b) have recently
been tested in red deer. RB51 and RB51 overexpressing superoxide
dismutase (sodC) and glycosyltransferase (wboA) genes has been
tested in bison (Olsen et al., 2009). These studies provide support
toward the development of a safe and effective vaccine for practical
animal uses.
CONCLUDING REMARKS
During the past decade, systems biology, and bioinformatics
approaches have widely been used for study of the mechanisms of
Brucella pathogenesis and host protective immunity against Bru-
cella infections and for support of vaccine design. This review arti-
cle demonstrates that integrative experimental Omics and com-
putational bioinformatics analyses have dramatically advanced
our understanding of how different Brucella species infect dif-
ferent host species, how Brucella gene expressions are regulated
in cell culture or inside host cells (i.e., macrophages or epithelial
cells), and how host cells (macrophages, epithelial cells, spleno-
cytes, and blood cells) respond to Brucella infections. Advanced
literature mining provides tools to retrieve and analyze virulence
factors, protective antigens, and host–Brucella gene interactions
from thousands of Brucella research publications. Machine and
human-readable Brucella Ontology and VO have provided more
ways to integrate Brucella data with other infectious diseases and
vaccine data.
One main message of the review is that systems biology and
bioinformatics approaches are able to help to facilitate vaccine
development and predict fundamental molecular mechanisms of
host–Brucella interactions.With the initial high throughput exper-
imental studies and advanced data analyses, many predictions can
be made and used as novel hypotheses for further conﬁrmation
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by “traditional” experimental approaches. The ﬁndings from the
Omics studies have opened new avenues of research.Many of these
studies conﬁrmed and expanded the results of classical approaches
in the areas of Brucella pathogenesis and host immunity against
Brucella infection or vaccination. From our literature data min-
ing analysis, known Brucella virulence factors can be retrieved.
Compared to any isolated study of Brucella virulence factor(s),
a systematical analysis of all possible virulence factors provides a
more comprehensive view of how Brucella survives and replicates
in a hostile intracellular environment and in vivo. In contrast to
the traditional vaccine development strategy of continuous trials
after isolated hypotheses, the new strategy that starts with sys-
tems biology and bioinformatics analyses make it possible to more
rationally design safe, effective, and optimized Brucella vaccines.
Although much progress has been made, many challenges
still exist. For example, while different gene expression proﬁles
have been discovered at different experimental conditions, how to
integrate these data and make sense of the interconnected host–
Brucella interaction mechanism remains a challenge. IDOBRU
and VO may provide ontology-based platforms for obtaining a
higher level of data and knowledge integration.However, currently
IDOBRU and VO only provide proof-of-concept demonstrations
for representing Brucella virulence factors and host immune
responses (Lin et al., 2011). Additional efforts are required to sys-
tematically apply IDOBRU/VO and related semantic web tools to
represent and analyze different levels of host–Brucella interaction
data and knowledge. Another challenge is how to improve the
translation of the knowledge learned from the systems and bioin-
formatics studies into the generation of new vaccines and drugs
against infectious Brucella infections? The Brucella gene expres-
sion data obtained under different experimental conditions may
be used to better design vaccine protein targets. The host response
proﬁles may facilitate a deeper understanding of the protective
immune response in the host. This will require diligent research
anddevelopment todesignnewways tomake all these translational
outcomes a reality.
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